Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 11/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 1.00 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703019 | 1.00 | EGLN2 (1.00) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL3703018 | 0.99 | EGLN2 (0.98) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| SCHEMBL14980827 | 0.92 | EGLN2 (0.85) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| SCHEMBL2572105 | 0.86 | EGLN2 (0.75) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL2569325 | 0.85 | EGLN2 (0.74) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL2570664 | 0.85 | EGLN2 (0.74) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| SCHEMBL2570669 | 0.84 | EGLN2 (0.72) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| Hydrochloric Acid SCHEMBL3706626 | 0.83 | EGLN2 (0.71) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| SCHEMBL3706371 | 0.82 | EGLN2 (0.69) | EGLN2EGLN1HIF1ANTET2OGFOD1 | |
| SCHEMBL4752104 | 0.81 | EGLN2 (0.68) | EGLN2EGLN1HIF1ANTET2OGFOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119876014-A | Anti-inflammatory mesenchymal stem cells and preparation method and application thereof | 杨业国 | 2025-04-25 | — | — | CN | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| CN-119365486-A | EPO receptor agonists and antagonists | 免疫先锋股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| EP-4490187-A2 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | Immunedge, Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| CN-117778303-A | Application of IOX4 in promoting anti-inflammatory activity of human umbilical mesenchymal stem cells | 恒峰铭成生物科技(上海)有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117778302-A | Application of IOX4 in treating umbilical mesenchymal exosomes and in delaying cell aging | 恒峰铭成生物科技(上海)有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117757734-A | Application of IOX4 in resisting human umbilical cord mesenchymal stem cell aging | 恒峰铭成生物科技(上海)有限公司 | 2024-03-26 | — | — | CN | claimed |
| WO-2023172989-A2 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE, INC. (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230201359-A1 | MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR DELIVERING THERAPEUTIC AGENTS TO HEART | ACADEMIA SINICA (TW) | 2023-06-29 | — | — | US | claimed |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | IMMUNEDGE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12540189-B2 | — | — | 2026-02-03 | — | — | US | disclosed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| CN-217443969-U | Wireless inspection system for ship lock | 南京洛普股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-20220257741-A1 | COMBINATION THERAPY FOR CANCER | IO BIOTECH APS (DK) | 2022-08-18 | — | — | US | disclosed |
| US-20220127257-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2022-04-28 | — | — | US | disclosed |
| WO-2022040798-A1 | COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-03 | — | — | WO | disclosed |
| US-11261179-B2 | Small molecules | UNIVERSITY OF DUNDEE (GB) | 2022-03-01 | — | — | US | disclosed |
| US-20220025324-A1 | METHODS OF PRODUCING VENOUS ANGIOBLASTS AND SINUSOIDAL ENDOTHELIAL CELL-LIKE CELLS AND COMPOSITIONS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | EGLN2 146/4885EGLN1 503/4885HIF1AN 37/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | EGLN2 5/4885EGLN1 3/4885HIF1AN 1/4885 |
| US-20220127257-A1 | SMALL MOLECULES | ADRM1, MDM2, UBE2B | EGLN2 1797/4885EGLN1 1343/4885HIF1AN 1799/4885 |
| US-12540189-B2 | — | EPOR, MPL, JAK2 | EGLN2 398/4885EGLN1 646/4885HIF1AN 119/4885 |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | EPOR, MPL, CSF3R | EGLN2 527/4885EGLN1 987/4885HIF1AN 122/4885 |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, STAT5A, JAK2 | EGLN2 407/4885EGLN1 746/4885HIF1AN 289/4885 |
| US-11261179-B2 | Small molecules | ADRM1, MDM2, UBE2B | EGLN2 1797/4885EGLN1 1343/4885HIF1AN 1799/4885 |
| US-20230201359-A1 | MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR DELIVERING THERAPEUTIC AGENTS TO HEART | FABP3, CD14, FABP1 | EGLN2 3401/4885EGLN1 3840/4885HIF1AN 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.